Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Furugaki, Kouichi ^a,b   Cui, Lin ^a   Kunisawa, Yumi ^a   Osada, Kensuke ^c   Shinkai, Kentaro ^b   Tanaka, Masao ^b   Kataoka, Kazunori ^c   Nakano, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GLYCOPROTEIN P 15095; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SART3 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MICELLE; RNA BINDING PROTEIN; SART3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CD4+ T LYMPHOCYTE; CD40L GENE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE; GENETIC TRANSFECTION; GM CSF GENE; HAPLOTYPE; HUMAN; HUMAN CELL; LIVER; LONG TERM SURVIVAL; LUNG CANCER; LYMPH NODE; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICELLE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; SART3 GENE; SPLEEN; T CELL DEPLETION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; GENETICS; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD40 LIGAND; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICELLES; RNA-BINDING PROTEINS;

EID: 84904154803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101854     Document Type: Article

References (43)

1. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF (2009) Dendritic cell-based cancer gene therapy. Hum Gene Ther 20: 1106-1118.
2. Andersen BM, Ohlfest JR (2012) Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 325: 155-164.
3. Lu L, Woo J, Rao AS, Li Y, Watkins SC, et al. (1994) Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 179: 1823-1834. (Pubitemid 24155663)
4. Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19: 1035-1043.
5. van de Laar L, Coffer PJ, Woltman AM (2012) Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119: 3383-3393.
6. Lazoura E, Apostolopoulos V (2005) Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem 12: 1481-1494. (Pubitemid 40872573)
7. Berzofsky JA, Terabe M, Wood LV (2012) Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol 39: 348-357.
8. Mackiewicz J, Mackiewicz A (2009) Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol 625: 84-89.
9. Barth RJ, Jr., Fisher DA, Wallace PK, Channon JY, Noelle RJ, et al. (2010) A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 16: 5548-5556.
10. Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, et al. (2005) A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 125: 173-181. (Pubitemid 40602390)
11. Katayose S, Kataoka K (1997) Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug Chem 8: 702-707. (Pubitemid 27416084)
12. Kakizawa Y, Kataoka K (2002) Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 54: 203-222. (Pubitemid 34230442)
13. Miyata K, Nishiyama N, Kataoka K (2012) Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. Chem Soc Rev 41: 2562-2574.
14. Kumagai M, Shimoda S, Wakabayashi R, Kunisawa Y, Ishii T, et al. (2012) Effective transgene expression without toxicity by intraperitoneal administration of PEG-detachable polyplex micelles in mice with peritoneal dissemination. J Control Release 160: 542-551.
15. Ohgidani M, Furugaki K, Shinkai K, Kunisawa Y, Itaka K, et al. (2013) Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and exhibits safety potentials in mice and cynomolgus monkeys. J Control Release 167: 238-247.
16. Chen Q, Osada K, Ishii T, Oba M, Uchida S, et al. (2012) Homo-catiomer integration into PEGylated polyplex micelle from block-catiomer for systemic anti-angiogenic gene therapy for fibrotic pancreatic tumors. Biomaterials 33: 4722-4730.
17. Miyata K, Oba M, Nakanishi M, Fukushima S, Yamasaki Y, et al. (2008) Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J Am Chem Soc 130: 16287-16294.
18. Itaka K, Ishii T, Hasegawa Y, Kataoka K (2010) Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity. Biomaterials 31: 3707-3714.
19. Uchida S, Itaka K, Chen Q, Osada K, Ishii T, et al. (2012) PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther 20: 1196-1203.
20. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, et al. (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056-4063. (Pubitemid 29393577)
21. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, et al. (2007) Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 56: 689-698. (Pubitemid 46348730)
22. Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, et al. (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88: 633-639.
23. Harada K, Yamada A, Mine T, Kawagoe N, Takasu H, et al. (2000) Mouse homologue of the human SART3 gene encoding tumor-rejection antigen. Jpn J Cancer Res 91: 239-247. (Pubitemid 30130755)
24. Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, et al. (2010) DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood 115: 653-656.
25. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH (2004) New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103: 2677-2682. (Pubitemid 38393024)
26. Hirano K, Hunt CA (1985) Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 74: 915-921. (Pubitemid 15014130)
27. Un K, Kawakami S, Suzuki R, Maruyama K, Yamashita F, et al. (2010) Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure. Hum Gene Ther 21: 65-74.
28. Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, et al. (2010) Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother 33: 630-638.
29. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, et al. (2006) Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 7: 740-746. (Pubitemid 43905873)
30. Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, et al. (2005) A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene Ther 12: 1049-1057. (Pubitemid 40946147)
31. Ciupitu AM, Petersson M, O'Donnell CL, Williams K, Jindal S, et al. (1998) Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 187: 685-691. (Pubitemid 28115184)
32. Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, et al. (2009) Role of GM-CSF signaling in cell-based tumor immunization. Blood 113: 6658-6668.
33. Ma DY, Clark EA (2009) The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 21: 265-272.
34. Wang Y, Zhang Y, Yoneyama H, Onai N, Sato T, et al. (2002) Identification of CD8alpha+CD11c- lineage phenotype-negative cells in the spleen as committed precursor of CD8alpha+ dendritic cells. Blood 100: 569-577. (Pubitemid 34761121)
35. Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, et al. (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103: 150-153.
36. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527. (Pubitemid 47535942)
37. Pan PY, Wang GX, Yin B, Ozao J, Ku T, et al. (2008) Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228.
38. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, et al. (2011) A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 253: 328-335.
39. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
40. Wang W, Lau R, Yu D, Zhu W, Korman A, et al. (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21: 1065-1077.
41. Tongu M, Harashima N, Monma H, Inao T, Yamada T, et al. (2013) Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 62: 383-391.
42. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72: 3439-3444.
43. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, et al. (2013) Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 133: 98-107.